2021 Global Pharmaceutical Company Revenue TOP20 Announced!

In 2021, for those biopharmaceutical companies that have launched COVID-19 products, performance has not been greatly affected despite the impact of the COVID-19 pandemic, while BioNTech and Moderna bucked the trend and grew by more than 2,000%. This article summarizes the top 20 biopharmaceutical companies ranked by global revenue in 2021, of which 12 companies have increased their sales by at least 10%, and 5 companies have even increased their sales by more than 40%.

Johnson & Johnson: $93.77 billion

Johnson & Johnson's global revenue reached $93.77 billion last year, up 13% from 2020, and its three main divisions are consumer health care, pharmaceuticals and medical devices. Among them, the pharmaceutical sector had the most revenue at $52 billion. The company's main growth drivers come from multiple myeloma drug Darzalex, immunology blockbuster Stelara and its COVID-19 vaccine. Darzalex's revenue topped $6 billion last year, up 44% year over year, while Stelara's sales, over $9 billion, were up 18.5% year over year. Additionally, the Consumer Healthcare business is the smallest of the three segments, with 2021 sales of $14.64 billion, up just 4% compared to 2020.

Pfizer: $81.29 billion

Pfizer's COVID-19 vaccine generated $37 billion in revenue last year, accounting for nearly half of Pfizer's $81.3 billion total. In addition, the company expects Comirnaty and Paxlovid to generate combined sales of $54 billion in 2022, with Comirnaty expected to generate $32 billion in revenue. Even excluding COVID-19 products, Pfizer's total revenue rose 6% last year to $44.4 billion. In the fourth quarter, however, sales of Pfizer's once-best-selling Prevnar pneumococcal vaccine fell 25%.

Roche: $68.7 billion

Roche's drug sales rose 3% in constant currency last year to CHF 45 billion, with the largest growth in the multiple sclerosis drug Ocrevus, the hemophilia drug Hemlibra, the inflammatory disease treatment Actemra and PD- The L1 inhibitor Tecentriq. Although Roche's performance will continue to grow in 2021, its three major cancer drugs Avastin, Herceptin and Rituxan have been severely hit by generics, with sales falling by $4.9 billion. To this end, Roche's attention is shifting to the introduction of new drugs.

AbbVie: $56.2 billion

In 2021, AbbVie's sales were $56.2 billion, up 22% from 2020, with $20.7 billion coming from its immunology blockbuster Humira, however, the company faces a slew of biosimilar competition in 2022, It's also the underlying reason behind AbbVie's focus on focusing its marketing efforts on Rinvoq and Skyrizi. The two drugs are currently FDA-approved for the treatment of psoriatic arthritis, atopic dermatitis, ulcerative colitis and plaque psoriasis, and are expected to generate $15 billion in revenue by 2025.

Novartis: $51.63 billion

Anti-inflammatory drug Cosentyx and cardiac drug Entresto remain Novartis' top-selling drugs and key performance growth drivers in 2021, with sales reaching $4.72 billion and $3.55 billion, respectively. Novartis' mergers and acquisitions will be in the spotlight in 2022, with the company still having some cash after it sold its Roche stake for $20.7 billion and launched a $15 billion share buyback program. Notably, sales at Sandoz, the company's generics business, fell 2% in 2021 to $9.6 billion.

Merck: $48.7 billion

In 2021, Merck's immuno-oncology superstar Keytruda's sales rose 20% from $14.4 billion to $17.2 billion. The Covid-19 treatment Molnupiravir was not approved for use in the U.S. until Dec. 23, but the pre-sale agreement helped it reach $952 million in fourth-quarter sales. HPV vaccine Gardasil revenue reached $5.7 billion, up 44%. However, Merck needs to solve the problem of over-reliance on Keytruda. By 2028, when Keytruda loses patent protection, whether it can realize the diversification of performance growth is the dilemma faced by the company.

Bristol-Myers Squibb: $46.4 billion

Bristol-Myers Squibb's revenue in 2021 will reach $46.4 billion, up 9% from $42.5 billion in 2020. Revlimid grew 6% last year, generating $12.82 billion in revenue, while blood thinner Eliquis had annual sales of $10.76 billion, up 17%. In immuno-oncology, Opdivo generated sales of $7.52 billion in 2021, up 8%, while Yervoy revenue fell by $2 billion. However, Bristol-Myers Squibb is optimistic that it will generate $45 billion to $50 billion in free cash flow over the next three years.

GlaxoSmithKline: $45.98 billion

GlaxoSmithKline's good performance in 2021 was helped by growth in sales of its COVID-19 antibody treatment sotrovimab, which it partnered with Vir Biotechnology, to 958 million pounds ($1.26 billion), 89% of which came from last year fourth quarter. Asthma and COPD therapy Trelegy had $1.6 billion in sales, and asthma drug Nucala also brought in $1.5 billion in sales. GSK said it expects biopharma sales to continue growing by 5%-7% in 2022 and believes it will return to the $46 billion mark in 2031.

Sanofi: $44.67 billion

Sanofi's full-year 2021 sales rose 7.1% to $44.67 billion, thanks to Dupixent and vaccines, with sales of immunology drugs at $6 billion. While Sanofi's vaccines business remained in the lead, the company's fourth-quarter global flu vaccine sales fell 12.4%. The situation was even more dire in the U.S. market, where flu vaccine sales plummeted 48.3% and sales fell 13.6% for the year. However, the company has now raised Dupixent's top-line forecast for future sales to more than $14.44 billion.

AstraZeneca: $37.42 billion

AstraZeneca's 2021 revenue is mainly affected by Alexion. In addition to the rare disease business, its oncology product portfolio is the biggest contributor to the company's performance growth. Four blockbuster drugs, EGFR inhibitor Tagrisso, PD-L1 blocker Imfinzi, PARP inhibitor Lynparza, and BTK blood cancer drug Calquence are in the first Both quarters ended with double-digit sales growth. However, the problem that AstraZeneca needs to face is that its performance in the Chinese mainland market will decline significantly from 2022.

Takeda: $31.55 billion

Takeda's best-selling inflammatory bowel disease drug, Entyvio, remains a key growth driver in 2021. In the first three quarters of last year, the drug's sales were 395.4 billion yen, a year-on-year increase of 23.8%. During the period, sales of multiple myeloma drug Velcade rose 11.3% to 84.5 billion yen. In contrast, sales of Takeda's new oral myeloma drug Ninlaro rose just 4.2%. In rare diseases, Takeda's hereditary angioedema market grew 10.7%, and plasma-derived therapy revenue rose 16% to 363.2 billion yen.

Eli Lilly: $28.32 billion

Eli Lilly's 2021 revenue of $28.32 billion, up 15% from the previous year's $24.54 billion, said in its February earnings report that if Eli Lilly's COVID-19 antibody sales were excluded, total global revenue Full-year revenue was up 10% at $2.239 billion. In the field of diabetes, global sales of Eli Lilly's GLP-1 drug Trulicity reached $6.472 billion, but the performance of insulin injection Humalog fell 7% to $2.453 billion. In 2022, the company expects global sales to be between $27.8 billion and $28.3 billion.

Bayer: $28.23 billion

Bayer's 2021 performance reversed, with revenue reaching 23.87 billion euros, with sales growth driven mainly by Eylea, which was up 19% from 2020. Eylea's performance also helped make up for lost profits from slower sales momentum at Xarelto. Sales of eight of the company's 15 top-selling products in 2021 increased by more than 10%, including blood pressure drugs Adalat ($834 million) and Adempas ($807 million), X-ray agent Ultravist ($390 million) and Birth control products Mirena/Kyleena/Jaydess ($1.28 billion) and YAZ/Yasmin/Yasminelle ($813 million).

Gilead: $27.3 billion

Without the launch of the new coronavirus drug Veklury, Gilead's performance revenue will decline significantly in 2020 and 2021. The company's overall sales rose 11% last year and are up 10% in 2020. But this trend is hard to sustain, and the company expects revenue to fall to $23.8 billion-$24.3 billion in 2022. In addition, Gilead's stagnant performance was partly blamed on weak sales of its HIV products, which fell from $16.9 billion in 2020 to $16.3 billion in 2021, including Descovy, Genvoya and Odefsey.

Amgen: $25.98 billion

Amgen achieved total revenue of $26 billion last year, up 2% from 2020. Amgen said the company's COVID-19 antibodies, produced in partnership with Eli Lilly, drove the growth. A major move for Amgen in 2021 is to announce 500 layoffs in the U.S., mostly in sales, and to shift its focus to new drug launches in order to adapt to its drug marketing strategy during the pandemic. In addition, Amgen is also investing more in biosimilars. At the JPMorgan healthcare conference earlier this year, Amgen said its biosimilars would reach $4 billion in sales by 2030.

Boehringer Ingelheim: $24.36 billion

In the absence of a COVID-19 product launch, the company has had a stable performance over the past three years. Last year, Boehringer Ingelheim's performance exceeded the 20 billion euro mark for the first time, an increase of 5%. Pharmaceuticals will grow 6% to $16.78 billion in 2021, animal health will grow 4% to $4.71 billion, and contract manufacturing will grow 10% to $993 million. The company had previously been optimistic that net sales would continue to grow slightly in 2022, with as many as 15 drugs approved by 2025.

Novo Nordisk: $22.38 billion

Novo Nordisk's revenue in 2021 reached $22.38 billion, a 14% increase from $20.24 billion in 2020. Performance growth points mainly include Ozempic, Rybelsus and semaglutide. Notably, the semaglutide franchise has soared in 2021 and received a landmark obesity treatment approval in June. Overall, Novo Nordisk expects total sales to grow 6%-10% in 2022, and in the obesity market alone, the company more than doubled its 2025 sales target in March.

BioNTech: $22.44 billion

Affected by its mRNA new crown vaccine, the company's performance increased by 3987% last year, and it has become a world-renowned biopharmaceutical company. In 2022, BioNTech expects vaccine sales to continue to generate €13 billion-€17 billion in revenue. However, while more doses of the vaccine may be brought to the market in the future, actual sales may actually be lower due to price discounts. In addition, BioNTech also admitted that after 2022, there will be great uncertainty in the sales performance of the new crown vaccine.

Moderna: $18.47 billion

Before the Covid-19 pandemic, few people outside the biopharmaceutical industry had heard of Moderna's name. Last year, its global revenue reached $18.47 billion, an increase of more than 22 times over 2020. The COVID-19 vaccine, Spikevax, accounted for the vast majority of total revenue ($17.7 billion), with a whopping 807 million doses sold globally. As for 2022, Moderna expects its global sales to reach $22 billion, and in order to achieve that, Moderna aims to deliver 3 billion doses of the new crown vaccine this year.

Huizhi: $17.81 billion

Huizhi was born from the merger of generic drug giants Mylan and Pfizer's Upjohn divisions in late 2020, with sales reaching $17.81 billion in the first year. This result was primarily attributable to solid performance in developed and emerging markets, as well as Japan, Australia, New Zealand and Greater China. Most notably, the company won regulatory approval for Semglee, a biosimilar of Sanofi's diabetes blockbuster Lantus. Viatris forecasts revenue of $17 billion to $17.5 billion in 2022, in line with recent earnings performance.